GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Innopharmax 4172.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

9.41

+4.09%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Innopharmax

Its shares trade on Taipei Exchange under the ticker 4172.TWO. It has been listed since 13 September 2012. In the fiscal year to 31 December 2025, it reported revenue of TWD 69.0m and a net loss of TWD 184.4m. At that date it held total assets of TWD 469.0m and shareholders' equity of TWD 419.2m.

InnoPharmax, Inc. engages in the development and commercialization of pharmaceutical products for the treatment of oncology and specialty. The company is headquartered in Taipei City, Taipei. The company went IPO on 2012-09-13. The firm mainly provides generic drugs, including Cyclosporine A, Tacrolimus, Imipenem, Cilastatin, Gadodiamide, Gadopentetate, Levodopa, Carbidopa and Entacapone, as well as new drugs, including Gemcitabine Oral, Bendamustine, AB01001 patch and Carvedilol CR, among others. The firm mainly distributes its products within domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
13 Sept 2012
Employees
34

Leadership

Pay as last reported

  • Mr. Chih-Hui LinChairman of the Board, since 2008
  • Weihua HaoGeneral Manager, Director, since 2006
  • Liqian ZhangDeputy General Manager
  • Siru ChenHead of Finance & Accounting
  • Mr. William ChungDirector
  • Hanbin GuoDirector
  • Qirui LiDirector
  • You-Li LiaoDirector
  • Lee-Shing FangIndependent Director
  • Mr. Ku-Tung LinIndependent Director
  • Xueru ZengIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • InnoPharmax develops generic drugs like Cyclosporine A and Tacrolimus for oncology treatment.
  • The company focuses on specialty pharmaceuticals including Gemcitabine Oral and Bendamustine.
  • InnoPharmax has a strong domestic market presence in Taiwan with 34 employees.

Weaknesses

  • InnoPharmax primarily relies on the domestic market in Taiwan for product distribution.
  • The company has limited international expansion beyond Taiwan's borders.
  • InnoPharmax's product portfolio includes only 34 employees and generic drugs.

Opportunities

  • InnoPharmax can expand into new markets within the Health Care sector in Asia.
  • The company may leverage its specialty drugs like AB01001 patch for global opportunities.
  • Growing demand for oncology treatments presents opportunities for InnoPharmax.

Threats

  • Competition from international pharmaceutical firms in the Health Care sector.
  • Regulatory changes in Taiwan could impact InnoPharmax's domestic operations.
  • Dependence on the domestic market makes InnoPharmax vulnerable to local economic shifts.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.